Literature DB >> 29935655

Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.

Ben W Mol1, Patrick M Bossuyt2, Sesh K Sunkara3, Juan A Garcia Velasco4, Christos Venetis5, Denny Sakkas6, Kersti Lundin7, Carlos Simón8, Hugh S Taylor9, Robert Wan10, Salvatore Longobardi11, Evelyn Cottell11, Thomas D'Hooghe12.   

Abstract

Although most medical treatments are designed for the average patient with a one-size-fits-all-approach, they may not benefit all. Better understanding of the function of genes, proteins, and metabolite, and of personal and environmental factors has led to a call for personalized medicine. Personalized reproductive medicine is still in its infancy, without clear guidance on treatment aspects that could be personalized and on trial design to evaluate personalized treatment effect and benefit-harm balance. While the rationale for a personalized approach often relies on retrospective analyses of large observational studies or real-world data, solid evidence of superiority of a personalized approach will come from randomized trials comparing outcomes and safety between a personalized and one-size-fits-all strategy. A more efficient, targeted randomized trial design may recruit only patients or couples for which the personalized approach would differ from the previous, standard approach. Multiple monocenter studies using the same study protocol (allowing future meta-analysis) might reduce the major center effect associated with multicenter studies. In certain cases, single-arm observational studies can generate the necessary evidence for a personalized approach. This review describes each of the main segments of patient care in assisted reproductive technologies treatment, addressing which aspects could be personalized, emphasizing current evidence and relevant study design.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ART; Personalized medicine; precision medicine; trial design

Mesh:

Year:  2018        PMID: 29935655     DOI: 10.1016/j.fertnstert.2018.04.037

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  14 in total

1.  What Features of Fertility Treatment do Patients Value? Price Elasticity and Willingness-to-Pay Values from a Discrete Choice Experiment.

Authors:  Elena Keller; Willings Botha; Georgina M Chambers
Journal:  Appl Health Econ Health Policy       Date:  2022-09-29       Impact factor: 3.686

2.  An Online Tool Using Basal or Activated Ovarian Reserve Markers to Predict the Number of Oocytes Retrieved Following Controlled Ovarian Stimulation: A Prospective Observational Cohort Study.

Authors:  Yong Han; Huiyu Xu; Guoshuang Feng; Kannan Alpadi; Lixue Chen; Haiyan Wang; Rong Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

3.  Fertility technologies and how to optimize laboratory performance to support the shortening of time to birth of a healthy singleton: a Delphi consensus.

Authors:  Giovanni Coticchio; Barry Behr; Alison Campbell; Marcos Meseguer; Dean E Morbeck; Valerio Pisaturo; Carlos E Plancha; Denny Sakkas; Yanwen Xu; Thomas D'Hooghe; Evelyn Cottell; Kersti Lundin
Journal:  J Assist Reprod Genet       Date:  2021-02-18       Impact factor: 3.412

Review 4.  Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).

Authors:  Human Fatemi; Wilma Bilger; Deborah Denis; Georg Griesinger; Antonio La Marca; Salvatore Longobardi; Mary Mahony; Xiaoyan Yin; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-05-11       Impact factor: 5.211

5.  Reduced FSH and LH action: implications for medically assisted reproduction.

Authors:  E Bosch; C Alviggi; M Lispi; A Conforti; A C Hanyaloglu; D Chuderland; M Simoni; N Raine-Fenning; P Crépieux; S Kol; V Rochira; T D'Hooghe; P Humaidan
Journal:  Hum Reprod       Date:  2021-05-17       Impact factor: 6.918

6.  Time as an outcome measure in fertility-related clinical studies: long-awaited.

Authors:  Sesh K Sunkara; Wenjing Zheng; Thomas D'Hooghe; Salvatore Longobardi; Jacky Boivin
Journal:  Hum Reprod       Date:  2020-08-01       Impact factor: 6.918

Review 7.  The Development of Gonadotropins for Clinical Use in the Treatment of Infertility.

Authors:  Bruno Lunenfeld; Wilma Bilger; Salvatore Longobardi; Veronica Alam; Thomas D'Hooghe; Sesh K Sunkara
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-03       Impact factor: 5.555

8.  The Role of hCG Triggering Progesterone Levels: A Real-World Retrospective Cohort Study of More Than 8000 IVF/ICSI Cycles.

Authors:  Raffaella De Cesare; Emanuela Morenghi; Federico Cirillo; Camilla Ronchetti; Valentina Canevisio; Paola Persico; Annamaria Baggiani; Maria Teresa Sandri; Paolo Emanuele Levi-Setti
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-23       Impact factor: 5.555

9.  Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.

Authors:  Klaus F Bühler; Robert Fischer; Patrice Verpillat; Arthur Allignol; Sandra Guedes; Emmanuelle Boutmy; Wilma Bilger; Emilia Richter; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-06-16       Impact factor: 5.211

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.